Home

Baker / Tisch Capital (GP), LLC

CIK 1244392 · last filed 2012-01-03

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$22.89M

Companies

7

Total Filings

28

Lifetime Open-Market Net

-$1.10M

Filer Profile

Reported Address
667 MADISON AVE
21ST FLOOR
NEW YORK, NY 10065
Phone
(212) 339-5600
State of Incorporation
DE
Formerly Known As
BAKER TISCH CAPITAL GP LLC (2004–2005)
Related Filers
JULIAN BAKER — 104 joint filings, latest 2012-01-04
FELIX BAKER — 90 joint filings, latest 2012-01-04
INCYTE CORP — 20 joint filings, latest 2010-09-23
14159 capital (GP), LLC — same reported address
Baker Biotech Capital (GP), LLC — same reported address
Baker Bros. Capital (GP), LLC — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VIROPHARMA INC (VPHM) Delisted 10%+ Owner 1,306 — — $32.1K 6 2011-05-13
INCY Director 181,362 $124.86 $22.64M $131.0K 8 2010-08-11
Ardea Biosciences, Inc./DE (RDEA) Delisted 10%+ Owner 99,636 — — $133.3K 1 2008-12-19
BCRX 10%+ Owner 27,277 $9.16 $249.9K $6.8K 1 2008-11-24
Seagen Inc. (SGEN) Delisted Director 365,645 $228.74 $83.64M -$1.52M 3 2008-03-14
ALLOS THERAPEUTICS INC (ALTH) Delisted 10%+ Owner 97,340 — — -$96.6K 3 2008-01-17
GENOMIC HEALTH INC (GHDX) Delisted Director 193,759 — — $213.3K 2 2007-03-13

Recent Filings · Page 2 of 3

28 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2008-01-23 Seagen Inc. (SGEN) Delisted Buy (P) +129,510 $1.16M EDGAR
2008-01-17 ALLOS THERAPEUTICS INC (ALTH) Delisted Buy (P) +1,197 $9.0K EDGAR
2008-01-16 INCY Buy (P) +2,169 $23.8K EDGAR
2008-01-14 ALLOS THERAPEUTICS INC (ALTH) Delisted Buy (P) +12,990 $96.7K EDGAR
2008-01-11 INCY Buy (P) +7,677 $84.0K EDGAR
2008-01-10 VIROPHARMA INC (VPHM) Delisted Buy (P) +10,872 $96.0K EDGAR
2007-12-19 INCY Buy (P) +9,920 $105.1K EDGAR
2007-12-12 INCY Buy (P) +18,098 $180.8K EDGAR
2007-11-21 INCY Buy (P) +636 $5.2K EDGAR
2007-11-13 INCY Buy (P) +4,884 $39.5K EDGAR
Showing 11–20 of 28
Page 2 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.